- Location
dry eye syndrome
"-
CF101 Drug Released Results From a 24 Week
Jan 2, 2014Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. (OTCBB:OPLI) ...
Tags: Can-Fite BioPharma, OphthaliX, placebo-controlled phase III study
-
Dry Eye Is Related to Air Pollution Along with Weather Conditions
Nov 19, 2013Residents of major cities such as Chicago or New York with high levels of air pollution have an increased risk of dry eye syndrome, U.S. researchers say. Dr. Anat Galor of the Miami Veterans Affairs Medical Center, assistant professor of ...
Tags: dry, eye, air pollution, weather condition
-
Can-Fite BioPharma Received a Patent Entitled From The European Patent Office
Sep 6, 2013Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...
Tags: Can-Fite BioPharma
-
Neuroptis Biotech Have Partnered to Optimize and Transfer The Production Process
May 23, 2012Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech have partnered to optimize and transfer the production process for ML7, a new compound for treating dry eye syndrome. The companies have ...
Tags: ML7, dry eye syndrome, company cooperation, chemical service
Related Products
-
100 Billion Probiotics Treat Dry Eye Syndrome and Enhance Eye Health
-
High Activity Bifidobacterium Breve Probiotic Supplement for Eye Health
-
High Activity Food-Grade Bifidobacterium Breve Probiotic Original Eye Remedy
-
Halal Bifidobacterium Breve Probiotic Dry Eye Syndrome Alleviation Supplement
-
High Activity Bifidobacterium Breve Probiotic Supplement for Dry Eyes
-
ISO22000 Certified Bifidobacterium Breve Probiotics Enhance Immune System
